Scheme Rating
IME Scheme Rating
Concentrated Flexi-cap Strategy: Sameeksha’s Equity AIF is essentially an identical replication of their PMS portfolio in an AIF structure. Sameeksha’s Equity Fund is a concentrated (15-30 stock), Flexi-cap strategy (ability to move across market capitalizations) that follows a GARP (Growth at the Right Price) approach to investing. The strategy allows for more aggressive cash calls based on market views, and hedging of the portfolio in case of expected market declines.
IME Strategy Rating
Highly recommended for aggressive investors : Sameeksha Capital’s credibility is built on the strong fundamental research credentials of its founder Bhavin Shah. Bhavin has worked as a top-rated senior analyst at JP Morgan & Credit Suisse, post which he headed Equirius Research prior to setting up Sameeksha Capital. The combination of a highly-pedigreed fundamental research driven-manager, robust research processes combined with proprietary research tools, and strong performance make Sameeskha a good boutique option amongst PMS firms.
PMS Scheme Ratings are driven by IME’s Proprietary Scheme Rating Methodology, which takes into account our ratings of the Scheme’s investment strategy, its maturity, the investment team, and our separate rating on the AMC that runs this particular scheme. Our views on each of these individual criteria are available via the IME RMS – which you can view by reaching out to one of our relationship managers (using either the live chat or book appointment feature on this site).
IME View on Sameeksha PMS
Emkay Capital Builder-Investment Strategy
Emkay PMS’s Capital Builder Strategy is a focused multi-cap strategy (20-25 stocks) that uses it’s proprietary E-Qual risk framework to ensure that no investments in low-quality companies slip into the portfolio. The investment framework involves a long-term investment approach in compounding stories backed by strong fundamental research.
Investment Process
To mitigate biasness, Emkay define a universe for selection of stocks and having a equal weight-age portfolio. In order for selecting stocks Emkay follow a rigorous framework from a universe of more than 5000 listed companies. In order to filter these companies the framework followed is:
Defined Market Cap Filter: Filtering top 250 companies as per market cap with focus on large and mid-cap having net sales more than Rs 500 cr.
Earnings Growth Filter: Focusing on businesses that have a strong historic and future growth stocks defined by businesses having ROCE>COE and their earnings growth> GDP growth. Filtering 130-140 companies.
Strong Leadership Framework Filter: Focusing on companies with strong leadership in terms of market share, profit share, cost, growth, product. These businesses also having strong management credentials in terms of vision, track record, growth.
Valuation: Selecting stocks finally by focusing on companies by looking at price-value gap through DCF with focus on marging of safety. Also having a comparative valuations, Mcap vs opportunity size, PEG ratio.
Trailing Performance
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sameeksha Equity Fund AIF | ||||||||||
| S&P BSE 500 TRI | ||||||||||
| Alpha (over Broad Mkt BM) | ||||||||||
| Nifty 500 | ||||||||||
| Alpha (over Category BM) |
Fund Managers
Sameeksha Equity Fund AIF
AMC
AMC: (click link for detailed AMC review)
Note: PMS AMC & Scheme Reviews and Ratings are based on IME Capital’s Proprietary Review and Rating Methodology (read more here: AMC Rating & Scheme Ratings). These reflect the unbiased views of our central research team, based on our assessment of the investment value of these PMS/AIF strategies for our investors. We follow a highly stringent rating-criteria, where approximately 50% of PMS AMC’s & strategies would be rated 2-star or below (this is not meant to indicate that these funds are not investment-worthy, but that they do not currently fulfill the requirements we focus on for recommending funds to our investors — based on our internal views on the merit of the AMC/strategy relative to peers). Reviews & Ratings are primarily based on research of publicly available information (SEBI disclosures, PMS websites, PMS-aggregation platforms, webinar recording, media interviews etc.) and no explicit consent is required from AMCs for the same. While we endeavour to do further due-diligence via direct interactions with the investment teams of AMCs, this is typically restricted to AMC’s that meet our foundational fund selection criteria (reviews on lower-rated AMCs are often based solely on publicly available information). The views reflected in our Reviews & Ratings, are our independent views and may not be shared by the AMC’s and the investment teams. Please read detailed disclaimer for more.